{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"16.4","value":"12.0"},{"groupId":"OG001","lowerLimit":"27.5","upperLimit":"38.8","value":"33.0"},{"groupId":"OG002","lowerLimit":"24.3","upperLimit":"35.2","value":"29.5"}]}],"title":"MMR at M6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.6","upperLimit":"27.6","value":"22.3"},{"groupId":"OG001","lowerLimit":"38.8","upperLimit":"50.7","value":"44.7"},{"groupId":"OG002","lowerLimit":"37.2","upperLimit":"49.1","value":"43.1"}]}],"title":"MMR at M12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.8","upperLimit":"43.4","value":"37.5"},{"groupId":"OG001","lowerLimit":"55.8","upperLimit":"67.4","value":"61.7"},{"groupId":"OG002","lowerLimit":"53.1","upperLimit":"64.9","value":"59.1"}]}],"title":"MMR at M24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.8","upperLimit":"44.5","value":"38.5"},{"groupId":"OG001","lowerLimit":"53.2","upperLimit":"65.0","value":"59.2"},{"groupId":"OG002","lowerLimit":"51.3","upperLimit":"63.2","value":"57.3"}]}],"title":"MMR at M36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.0","upperLimit":"49.8","value":"43.8"},{"groupId":"OG001","lowerLimit":"54.0","upperLimit":"65.7","value":"59.9"},{"groupId":"OG002","lowerLimit":"49.1","upperLimit":"61.1","value":"55.2"}]}],"title":"MMR at M48"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.2","upperLimit":"55.1","value":"49.1"},{"groupId":"OG001","lowerLimit":"56.8","upperLimit":"68.4","value":"62.8"},{"groupId":"OG002","lowerLimit":"55.2","upperLimit":"66.9","value":"61.2"}]}],"title":"MMR at M60"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.9","upperLimit":"47.7","value":"41.7"},{"groupId":"OG001","lowerLimit":"46.5","upperLimit":"58.4","value":"52.5"},{"groupId":"OG002","lowerLimit":"51.6","upperLimit":"63.5","value":"57.7"}]}],"title":"MMR at M72"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.5","upperLimit":"46.3","value":"40.3"},{"groupId":"OG001","lowerLimit":"44.0","upperLimit":"56.0","value":"50.0"},{"groupId":"OG002","lowerLimit":"44.9","upperLimit":"56.9","value":"50.9"}]}],"title":"MMR at M84"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.8","upperLimit":"43.4","value":"37.5"},{"groupId":"OG001","lowerLimit":"40.2","upperLimit":"52.1","value":"46.1"},{"groupId":"OG002","lowerLimit":"40.3","upperLimit":"52.3","value":"46.3"}]}],"title":"MMR at M96"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.8","upperLimit":"43.4","value":"37.5"},{"groupId":"OG001","lowerLimit":"37.4","upperLimit":"49.3","value":"43.3"},{"groupId":"OG002","lowerLimit":"34.4","upperLimit":"46.2","value":"40.2"}]}],"title":"MMR at M108"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.8","upperLimit":"42.3","value":"36.4"},{"groupId":"OG001","lowerLimit":"32.3","upperLimit":"43.9","value":"37.9"},{"groupId":"OG002","lowerLimit":"33.4","upperLimit":"45.1","value":"39.1"}]}],"title":"MMR at M120"}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"282"},{"groupId":"OG002","value":"281"}],"units":"Participants"}],"description":"MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated","id":"OG000","title":"Imatinib 400 mg QD"},{"description":"Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.","id":"OG001","title":"Nilotinb 300 mg BID"},{"description":"Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.","id":"OG002","title":"Nilotinib 400 mg BID"}],"paramType":"NUMBER","populationDescription":"Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.","reportingStatus":"POSTED","timeFrame":"6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months","title":"Rate of MMR at 6 Months and Beyond in All 3 Treatment Arms","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}